Posted inMarket
DA Davidson Maintains JFrog Stock Rating Amid High Software Security Demand
DA Davidson reaffirms its rating on JFrog stock, highlighting robust market demand for advanced software supply chain security solutions.
Posted inMarket
Freedom Broker Upgrades Argan Stock Following Exceptional Project Execution
Freedom Broker upgrades Argan stock rating, highlighting robust project execution and strong financial performance in the energy infrastructure sector.
Posted inMarket
Mama’s Creations Stock Price Target Reaffirmed at $25 by StoneX
StoneX has reaffirmed its price target for Mama's Creations stock at $25, maintaining a positive outlook for the company's financial growth.
Posted inMarket
UBS Lowers Six Flags Price Target Following Soft Q2 EBITDA Results
UBS reduces its stock price target for Six Flags following weaker-than-expected second-quarter EBITDA performance.
Posted inMarket
Needham Adjusts Planet Labs Stock Price Target Following Revenue Shift
Needham lowers its price target for Planet Labs shares due to a shift in revenue timing, maintaining a specific rating on the stock.
Posted inMarket
H.C. Wainwright Reaffirms Ionis Stock Rating Following Zanvastro Approval
H.C. Wainwright maintains its stock rating for Ionis Pharmaceuticals following the regulatory approval of Zanvastro, highlighting market confidence.
Posted inMarket
Oppenheimer Maintains Perform Rating on Ambarella Stock
Financial analysts at Oppenheimer have officially reiterated their Perform rating for Ambarella stock following recent market developments.
Posted inMarket
Raymond James Lowers Dycom Industries Price Target Amid Guidance Worries
Discover why Raymond James reduced its stock price target for Dycom Industries following recent financial guidance updates and market concerns.
Posted inMarket
Baird Increases Climb Bio Stock Price Target Following Trial Data
Financial firm Baird has raised its price target for Climb Bio stock to $25 following recent clinical trial data updates.
